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Abstract
Background: Antibody serology is an important tool in the investigation of celiac disease (CD),
but does not always correlate with mucosal appearance in the small intestine. Patients with positive
CD serology but normal mucosa (Marsh 0) are at increased risk of future CD. In this study we
describe a model for identifying and characterizing individuals with normal mucosa but positive CD
serology. Such individuals are sometimes referred to as having latent CD.
Methods: The records of ten Swedish pathology departments were used to identify individuals
with biopsies indicating normal duodenal/jejunal mucosa. Using the national personal identification
number, these data were linked with CD serology data (antigliadin, antiendomysial and tissue
transglutaminase antibodies); and we thereby identified 3,736 individuals with normal mucosa but
positive CD serology. Two independent reviewers then manually reviewed their biopsy reports to
estimate comorbidity. We also randomly selected 112 individuals for validation through patient
chart review.
Results: The majority of the 3,736 individuals were females (62%). Children (0–15 years) made up
21.4%. The median number of biopsy specimen was 3. Our review of biopsy reports found that
other gastrointestinal comorbidity was rare (inflammatory bowel disease: 0.4%; helicobacter pylori
infection: 0.2%). Some 22% individuals selected for patient chart review had a relative with CD. The
most common symptoms among these individuals were diarrhea (46%) and abdominal pain (45%),
while 26% had anemia. Although 27% of the individuals selected for validation had been informed
about gluten-free diet, only 13% were adhering to a gluten-free diet at the end of follow-up.
Conclusion:  Individuals with positive CD serology but normal mucosa often have CD-like
symptoms and a family history of CD.
Background
Celiac disease (CD) is an immune-mediated disorder usu-
ally confirmed through small-intestinal biopsy[1,2]. In
the last 10–15 years, the use of CD serology (antigliadin
antibodies (AGA)[3], antiendomysial antibodies
(EMA)[4,5], and tissue transglutaminase antibodies
(TTGA) [6-8])[9] has changed the diagnostic algorithm
for CD [10]. At first, only AGA was used, but recently, this
antibody has been largely replaced by EMA and TTGA
except in young children. We have earlier shown that 68/
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68 (100%) Swedish pediatricians and 141/180 (78%)
adult gastroenterologist use CD serology in their work-up
for CD in at least 90% of individuals with suspected
CD[11]. More than 95% of Swedish pediatricians and
adult gastroenterologists perform a small intestinal
biopsy prior to a diagnosis of CD [11].
In individuals with CD, the biopsy typically shows villous
atrophy (VA), crypt hyperplasia and inflammation
[12,13]. However, some individuals with positive CD
serology have a normal mucosa (Marsh 0). Many of those
later develop CD [14-17], and the term "latent CD" is
sometimes used when referring to such individuals [18].
We linked Swedish biopsy registers with biochemistry reg-
isters to identify individuals with positive CD serology but
normal small intestinal mucosa. The purposes of this
paper were to (I) describe a model for identifying such
patients, (II) describe the symptoms and signs in a subset
of patients, and to (III) evaluate if registry-matching is an
effective means to identify individuals with positive CD
serology but normal small intestinal mucosa.
Methods
Patients were identified through matching of normal
biopsy data (obtained from pathology departments) and
data on positive CD serology (obtained from biochemis-
try departments).
Classification of biopsy data
To exclude a diagnosis of CD, Swedish pathologists will
examine the crypt-villous ratio, the different layers of the
intestine, and the number of intraepithelial lymphocytes
in small intestinal biopsies. All Swedish pathology depart-
ments also use CD3 immunostaining to detect intraepi-
thelial lymphocytosis [11] (classified as inflammation
(Marsh 1–2) in Sweden). For a description of the Swedish
SnoMed system, and a complete listing of histopathology
codes used in this study please see Additional File 1. In the
current study, we defined normal mucosa (Marsh 0) [19]
as either of the SnoMed codes, M0010 and M0011.
Collection of biopsy data
Biopsy data collection took place between the 27th of
October 2006 and the 12th of February 2008. Through
computerized searches of all regional pathology depart-
ments we obtained 351,403 unique small intestinal biop-
sies (normal mucosa, inflammation or VA) [11], from
287,586 separate individuals. A detailed description of
the data collection has been published earlier [11]. In
total there were 244,992 biopsies with normal mucosa.
We then identified all individuals who had had a normal
biopsy, but never a biopsy with inflammation or VA from
ten pathology departments throughout the study period
(n = 121,952 individuals)(Figure 1). Using the unique
personal identity number (assigned to more than 99% of
all Swedish residents) normal biopsy data were matched
with CD serology data on a regional basis. The following
university hospitals contributed serology data: Karolinska
Hospital Solna, Karolinska Hospital Huddinge, Sahlgren-
ska Hospital, Östra Hospital, Malmö Hospital, Lund Hos-
pital, Uppsala Hospital, and Örebro Hospital. For each
CD serology sample we obtained data on date of test, type
of test (AGA, EMA, TTGA), antibody levels, IgG/IgA and
age-specific reference values at the time of testing. In this
study we identified individuals with normal mucosa but
positive CD serology up to 180 days before biopsy, and
until 30 days after biopsy. Patient data were only included
for those who had never had a biopsy showing inflamma-
tion or VA (until year 2008). A total of 3,736 individuals
fulfilled these criteria (Figure 1).
Misclassification of individuals identified through registry 
matching
From among the 3,736 individuals, we randomly selected
120 identified through registry matching (EMA+: n = 40;
AGA+: n = 40; TTGA+: n = 40), and requested their patient
Identification of individuals with latent CD Figure 1
Identification of individuals with latent CD. By linkage 
of biopsy registers and CD serology registers we identified 
40,250 individuals with normal mucosa (and no biopsy record 
of CD or inflammation) with at least one test for CD serol-
ogy. 7,324 had at some stage a positive CD serology. Some 
50% of these (N = 3,736) had a positive CD serology at time 
of biopsy. 3,285 (87.9% of individuals with latent CD) had 
positive IgA, while 451 had positive IgG CD serology. Of 
3,736 individuals with latent CD, 228 had positive IgA EMA; 
3,117 had positive IgA AGA; and 161 had positive IgA TTGA. 
IgG EMA 1; IgG AGA 491; IgG TTGA 4. Due to overlap this 
exceeds 3,736). 303 individuals with IgA AGA had at least 2 
positive IgA AGA values within the stipulated time frame (2 
positive tests: IgG AGA 164; IgA TTGA 10).BMC Gastroenterology 2009, 9:57 http://www.biomedcentral.com/1471-230X/9/57
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charts from the department or health care centre that
requested the CD serology test, as well as from the depart-
ment performing the small intestinal biopsy (usually
departments of internal medicine/gastroenterology, sur-
gery or pediatrics).
Using individual medical records (and when missing
through phone contact with the responsible department/
physician), we assessed the proportion of individuals who
were correctly identified as having a macroscopically nor-
mal mucosa but positive CD serology, and who had never
had a biopsy with inflammation or VA).
Again using medical records, we then examined symp-
toms, signs, laboratory measures, and the extent to which
individuals had received information about gluten-free
diet. This information was divided according to type of
CD serology, and is presented both summarized and
weighted according to the distribution of EMA+, TTGA+
and AGA+ among the 3,736 individuals from the com-
plete data-set.
Comorbidity in biopsy samples
In order to determine if the positive CD serology could be
due to other concomitant gastrointestinal disorder (other
than pre-stage CD) or systemic disorders with gastrointes-
tinal involvement, we performed a computerized search
of the text of the 3,736 biopsy reports with normal
mucosa but positive CD serology (see also our earlier
paper on VA and inflammation [11]). Thereby we identi-
fied 67 biopsy reports where there were indications of
comorbidity other than CD. Each of these biopsy reports
was then manually screened by two independent review-
ers (JFL and research assistant) to confirm or reject the
presence of comorbidity. Discrepancies were resolved
through a third review of the biopsy reports where neces-
sary.
Quality assurance and accreditation of CD serology
To explore the quality of CD serology in Sweden we
obtained data from the organization Equalis, which has
provided laboratory quality assurance in Sweden since
1999 http://www.equalis.se/. The quality assurance
scheme can be described briefly as follows. Each year, one
of the participating laboratories submits eight blinded CD
serology samples to Equalis and a short accompanying
clinical description of the individual. From among these
eight samples (some positive, some negative for CD serol-
ogy), Equalis distributes two samples to all participating
laboratories for analysis and test data are then reported to
Equalis. All assurance data are then merged and presented
in aggregated form.
Equalis also provides accreditation of CD serology, and
we estimated the proportion of CD serology samples that
were accredited and originated from individuals with a
small intestinal biopsy (with normal mucosa, inflamma-
tion, or VA) in any of the ten participating pathology
departments[11]. We then estimated the proportion of
accredited CD serology samples from any individual
undergoing biopsy in the ascertainment area of these bio-
chemistry departments (independent of the histopathol-
ogy of the patient).
Statistics
We calculated 95% confidence intervals (CI). In post-hoc
analyses we compared the prevalence of symptoms and
signs according to the type of CD serology (EMA vs. AGA
vs. TTGA) using the Chi-2 test (Kruskal-Wallis test was
used when we examined year of biopsy and age at first
biopsy). To decrease the risk of false-positive statistical
significance due to multiple testing we used the Bonfer-
roni correction when comparing the patient characteris-
tics according to CD serology subtype [20]; and statistical
significance level was set to <0.003 (0.05/18 compari-
sons) [20].
Ethics
The current study was performed as part of a larger project
on complications in CD. That study was approved by the
Regional Ethical Review Board in Stockholm on the 4th of
June 2006 (2006/633-31/4) with additional amendments
(2007/747-32 and 2008/257-32).
Results
We identified 3,736 individuals with normal mucosa but
positive CD serology (Figure 1). The majority were female
and had reached adulthood at first biopsy (Table 1). Most
individuals had positive IgA AGA, mirroring the early
introduction of AGA in Swedish clinical practice (Table
2). Exact numbers of different antibodies are given in the
legend of Figure 1. Some 22% of individuals (95% CI =
15–32%) had a relative with a diagnosis of CD (Table 2).
Due to missing data we evaluated misclassification (see
below) in 114 individuals; and symptoms and signs in
Table 1: Characteristics of individuals with latent celiac disease
Latent CD
Number 3,736
Age, yrs (median, range) 36; 0–91
Children = 15 years (%) 21.4
Children = 21 years (%) 27.9
Females (%) 62.1
Entry year (median, range) 2001; 1990–2007BMC Gastroenterology 2009, 9:57 http://www.biomedcentral.com/1471-230X/9/57
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Table 2: Clinical characteristics of latent CD – patient chart review.
EMA;
N = 38
AGA;
N = 36
TTGA;
N = 38
Total;
N = 112
Total Weighted
N = 3,736
Background data
Females 26 (68) 24 (67) 25 (66) 75 (67) -
Age at first biopsy: median, range (years) 13 (2–80) 34 (1–91) 34 (1–75) 29 (1–91) -
Year of biopsy, median* 2003 2001 2006 2004 -
Reported heredity for CD 12 (32) 7 (19) 6 (16) 25 (22) 20%
Other diseases
Diabetes Mellitus, type 1 3 (8) 1 (3) 4 (10) 8 (7) 3%
Depression 1 (3) 4 (11) 8 (21) 13 (12) 11%
Thyroid disease 2 (5) 3 (8) 7 (18) 12 (11) 9%
Liver disease or increased liver enzymes 3 (8) 4 (11) 4 (10) 11 (10) 11%
Symptoms
Any gastrointestinal symptom# 31 (82) 32 (89) 32 (84) 95 (85) 88%
Diarrhea 16 (42) 18 (50) 17 (45) 51 (46) 49%
Weight loss/growth failure 9 (24) 7 (20) 7 (18) 23 (20) 20%
Abdominal pain 14 (37) 18 (50) 18 (47) 50 (45) 49%
Constipation 10 (26) 4 (11) 6 (16) 20 (18) 12%
Fatigue 6 (16) 6 (17) 5 (13) 17 (15) 16%
Laboratory data
Anemia and/or iron-deficiency 5 (13) 12 (33) 12 (32) 29 (26) 32%
Folic acid deficiency 2 (5) 0 (0) 4 (10) 6 (5) 1%
B12-deficiency 4 (10) 2 (6) 5 (13) 11 (10) 6%
Erythrocyte sedimentation rate, increased 0 (0) 2 (6) 3 (8) 5 (4) 5%
Percentages are given within brackets. Although latent CD was evaluated in 120 individuals, data on symptoms and signs (± laboratory measures) 
were only available in 112 individuals (93.3%).
EMA = Endomysial antibodies. AGA = Antigliadin antibodies. TTGA = Tissue transglutaminase antibodies.
Weighted percentages were estimated to mirror the full sample of study participants.
*Only for year of biopsy was there a statistically significant difference according to CD serology subtype when we corrected for multiple testing 
(Bonferroni correction [20]. There was no statistically significant difference in prevalence of any symptom or sign according to CD serology 
subtype.
#Weight loss was included among "any GI symptom". Also reflux symptoms (not listed above); nausea and abdominal gases were included among 
"any GI symptoms".
Additional information: Two individuals had a diagnosis of inflammatory bowel disease (IBD), both were positive for TTGA. Another two individuals 
had a diagnosis of dermatitis herpetiformis, both were positive for EMA.BMC Gastroenterology 2009, 9:57 http://www.biomedcentral.com/1471-230X/9/57
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112 individuals with normal mucosa but positive CD
serology.
Misclassification of individuals identified through registry 
matching (n = 114)
Through patient chart reviews we were able to confirm
that 103/114 (90.4%; 95% CI = 83–95%) individuals
identified through our registry matching had normal
mucosa but positive CD serology (and no biopsy with
inflammation or VA) (Figure 2).
The mean number of biopsy specimens at the first nega-
tive biopsy was 2.8 (median = 3). Since several individuals
were biopsied on more than one occasion, the estimated
mean number of biopsy specimens with normal mucosa
collected throughout the entire study period was 3.2.
Symptoms and signs in individuals with normal mucosa but 
positive CD serology (n = 112)
Diarrhea was seen in 46% of individuals (95% CI = 36–
55%), and constipation in 18% (95% CI = 11–26%). Ane-
mia occurred in 26% of the individuals (95% CI = 18–
35%), while B12 deficiency occurred in one out of ten
individuals (Table 2). Depression and liver disease were
both seen in about 10% of individuals with normal
mucosa but positive CD serology. Type 1 diabetes melli-
tus occurred in 8% of individuals and thyroid disease in
11%.
When we restricted our data to children (n = 39), diarrhea
was seen in 49% (95% CI = 32–65%), weight loss/growth
failure in 38% (95% CI = 23–55%), constipation in 28%
(95% CI = 15–45%), and anemia in 18% (95% CI = 8–
34%). There were no statistically significant differences in
symptoms and signs in comparisons using the various
Overview of individuals with latent CD Figure 2
Overview of individuals with latent CD. *Three individuals were suspected to have reduced the amount of dietary gluten 
prior to biopsy (due to other family member with CD). A fourth individual had abstained from gluten at an earlier stage but 
consumed a normal diet at time of biopsy. The most common reason for misclassification was presence of an earlier unre-
corded biopsy with villous atrophy (6.1%).BMC Gastroenterology 2009, 9:57 http://www.biomedcentral.com/1471-230X/9/57
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measures of CD serology, EMA+, AGA+, TTGA+, (data not
shown).
Information about gluten-free diet
Some 25% of the individuals with normal mucosa but
positive CD serology had received information about glu-
ten-free diet from a physician or a dietician (Table 3).
More individuals with positive EMA than positive AGA or
TTGA had received information about gluten-free diet,
although these differences are not statistically significant
after correction for multiple testing (data not shown).
However, only 13% (95% CI = 8–21%) were on a gluten-
free diet at the end of follow-up of this study (year 2008).
Comorbidity in biopsy samples
Diagnosed comorbidity was rare. There were 14 diagnoses
of IBD (in 3,736 patients; i.e. 0.4%; 95% CI = 0.2–
0.4%)(Table 4). Helicobacter pylori infection was men-
tioned in 9 biopsy reports (0.2%; 95% CI = 0.1–0.5%).
Accreditation of CD serology
Almost all IgA serology in individuals undergoing small
intestinal biopsy had been accredited (Table 5). However,
there is no accreditation of IgG CD serology in Sweden. As
part of the accreditation procedure, CD serology is tested
in a blinded manner in the biochemistry department seek-
ing accreditation. The validation and accreditation is car-
ried out by the non-profit company Equalis http://
www.equalis.se/. In 2007, the participating laboratories
were sent one positive and one negative sample, and
showed high consistency between different laboratories:
IgA AGA (17/17 positive samples were detected and 14/14
negative samples were correctly assessed), IgA EMA (18/
19 and 4/4) and IgA TTGA (18/19 and 17/18). The labo-
ratories themselves chose the appropriate assay. It is likely
that several laboratories performed the transglutaminase
IgA first, and finding it negative in "sample 2" did not per-
form the IgA EMA test (which was tested in only 4 labora-
tories).
Discussion
Through biochemistry registers and biopsy registers we
were able to identify 3,736 individuals with normal
mucosa but positive CD serology. Such individuals are at
increased risk of future CD[15,21]. Our patient chart
review found that more than 90% of individuals identi-
fied through matching of biopsy registers and biochemis-
try registers were correctly identified. Previous data
suggest that normal mucosa (Marsh 0) is very seldom mis-
classified (in a blinded test, 96% of samples with normal
mucosa were correctly classified by Swedish pathologists
[11]). In addition all surveyed Swedish pathology depart-
ments use CD3-immunostaining to detect intraepithelial
lymphocytes[11]. Most Swedish pathology departments
consider >30 intraepithelial lymphocytes per 100 as
abnormal[11] (and not >40 as was suggested in older lit-
Table 3: Gluten-free diet in latent CD (%).
EMA;
N = 38
AGA;
N = 36
TTGA;
N = 38
Total;
N = 112
Total Weighted
N = 3,736
Informed about gluten-free diet by physician or dietician 17 (45) 5 (14) 8 (21) 30 (27) 16%
Clinical response to gluten-free diet* 9/17 (53) 2/5 (40) 4/8 (50) 15/30 (50) 41%
Gluten-free diet at end of follow-up 10 (26.3) 1 (3) 4 (11) 15 (13) 5%
This table shows the proportion of individuals with latent CD that were encouraged to follow a gluten-free diet at some stage, as well as the 
proportion of individuals on a gluten-free diet at the end of follow-up (until year 2008).
* Percentages were calculated based on the number of individuals receiving information about gluten-free diet.
Table 4: Comorbidity in 67 biopsy samples – Results of manual 
examination
Histopathology Normal/Latent CD
Samples, No. 3,736 (%)
Gastric metaplasia 4 (0.1)
Helicobacter pylori infection 9 (0.2)
Mb Crohn 1 (<0.1)
Colitis: Microscopic/Ulcerative 11 (0.3)
Any IBD* 14 (0.4)
We also searched plain biopsy text for autoimmune enteropathy, 
giardiasis, inflammatory granuloma, lymphoma, other cancer, tropical 
sprue, postoperative changes, systemic lupus Erythematosus, 
vasculitis, Whipple's disease, immune deficiency, Behcet's disease, 
graft vs. host disease/transplantation, sarcoidosis, immunoglobuline 
disease and Zollinger-Ellison Disease. For these disorders, the 
computerized search only yielded results that were rejected on 
manual examination.
*Includes biopsy reports where non-specific IBD was listed.BMC Gastroenterology 2009, 9:57 http://www.biomedcentral.com/1471-230X/9/57
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erature[12]). Recent data indicate that a cut-off of 25 per
100[22] or 30 per 100 is appropriate [23].
The symptoms and signs of the 112 individuals whose
patient charts were reviewed in this study were similar to
those seen in CD [11,24,25]. This is however unsurpris-
ing, since most individuals in our cohort had probably
been tested for CD serology and undergone small intesti-
nal biopsy due to suspected CD. Earlier studies have
found a varying prevalence of diarrhea in individuals with
CD (Green: 85%[26]; Ciacci 60%[24]; Ludvigsson (chil-
dren) 53%[27]; Fasano 35%[28]). This compares with
45% in the current study of individuals with a normal
mucosa.
Some 85% of individuals in this study reported at least
some kind of gastrointestinal symptoms. This was slightly
higher proportion than in the study by Salmi et al (18/25
individuals (72%) with positive CD serology and Marsh
0–1 in their study had "abdominal symptoms")[16], but
then we also included weight loss in our definition of gas-
trointestinal symptoms. The prevalence of constipation in
the current study was almost identical to that of individu-
als with screening-detected CD in the Fasano et al study
[28]. In a British study, 50% of individuals with undiag-
nosed CD had anemia on presentation [29], and this may
partly be due to occult gastrointestinal bleeding [30].
Occult bleeding is however related to the degree of
mucosal injury[30], and that may explain the lower rate of
anemia in our population since they all had Marsh 0. Of
our individuals, one in four had anemia and/or iron defi-
ciency. Of note, we found no difference in the prevalence
of symptoms and signs according to the type of CD serol-
ogy (EMA+, AGA+, TTGA+).
Table 5: CD serology – Accreditation of laboratories.
Laboratory Analyses Accreditation Date Number of serology tests Accredited proportion*
Endomysial (IgA) 29-jan-98 6,755 95.5
Örebro Gliadin (IgA) 29-jan-98 3,737 91.9
Transglutaminase (IgA) 19-dec-01 2,974 95.7
Karolinska Solna and 
Huddinge§
Endomysial (IgA) 1996 8,243 98.0#
Gliadin (IgA) 1995 28,422 95.7#
Transglutaminase (IgA) 2002 20,042 93.4#
Sahlgrenska and Östra 
Hospitals§
Endomysial (IgA) 1997 10,855 98.4#
Gliadin (IgA) 1997 17,426 72.2#
Transglutaminase (IgA) 12-jun-03 1,100 100.0
Lund and Malmö Hospitals§ Endomysial (IgA) 19-dec-96 18,884 91.9
Gliadin (IgA) 19-dec-96 14,910 79.5
Transglutaminase (IgA) 2001 2,268 99.8#
Uppsala Gliadin (IgA) 1999 7,166 33.8#
Endomysial (IgA) 1999 3,470 65.1#
Transglutaminase (IgA) 1999 1,675 100#
*Proportion of IgA serology samples analyzed after accreditation date. IgG serology samples are not accredited in Sweden.
§Accreditation dates were the same for laboratories from the same university city/region (listed together above).
#When estimating the proportion of IgA CD serology samples analyzed after accreditation date, we have assumed that accreditation took place on 
the 1st of July the relevant year.BMC Gastroenterology 2009, 9:57 http://www.biomedcentral.com/1471-230X/9/57
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Twenty-two percent of validated individuals had a family
history of CD. This is consistent with data from an Amer-
ican study of adults with diagnosed CD [26], where 19%
reported having a relative with CD. There are several stud-
ies suggesting that individuals with CD are at increased
risk of having a relative with a diagnosis of CD [28,31,32],
but to our knowledge ours is the first study to show this in
individuals with normal mucosa but positive CD serol-
ogy.
The specificity of CD serology is high [16], and a negative
CD serology will almost always rule out a diagnosis of CD
[33]. However the positive predictive specificity (PPV) of
CD serology is not infallible, with two recent papers
showing a PPV for TTGA of 29% [33] and 76% [20]
respectively. This does not mean that positive CD serology
in individuals with normal mucosa is of no clinical signif-
icance. Many individuals with positive CD serology but
normal mucosa will go on to develop VA [14-17]; and IgA
AGA+[34], EMA+[34], and TTGA+[35] are all associated
with increased mortality.
Due to the historical nature of this study, AGA was the
only available screening tool for much of the study period
(beginning in 1990). AGA has lower specificity for CD
than TTGA and especially EMA[36]. Although we cannot
rule out the possibility that some individuals with posi-
tive CD serology and normal mucosa do not suffer from a
raised risk for future CD it should be emphasized that the
specificity of IgA AGA is nevertheless above 80% in adults
[36] (around 90% in a later report by Rostom et al [2]). In
children it may be even higher [36] (and more than 20%
of our population consisted of children aged 15 years).
These antibody tests were not performed as part of screen-
ing for CD in the general population but likely due to
symptoms that also merited a small intestinal biopsy.
Still, it should be remembered that not all individuals
with positive CD serology develop CD [16], and that pos-
itive CD serology can sometimes be transient.
We chose to include individuals with positive IgG and
normal mucosa in this study. IgA deficiency is strongly
associated with CD [37-39], and in these individuals IgG
is a frequently used screening tool for CD; and all individ-
uals in our study had undergone small intestinal biopsy.
Although IgG EMA and TTGA are associated with CD [40],
less is known of the specificity and positive predictive
value of IgG AGA.
Another potential limitation of our study is that some
biopsy samples may have been misclassified. Small intes-
tinal inflammation is sometimes missed by pathologists
[11], and in patchy VA[41] and inflammation, several
biopsies are needed to confirm a CD diagnosis [42,43].
Our study was based on historical data, when the use of
capsule biopsy was widespread (with fewer biopsy speci-
men as a consequence), especially among pediatricians
[11]. On average, 3 biopsy specimens had been obtained
from each individual, and some of the individuals may
have had a false-negative patchy VA. Neither can we rule
out that some individuals classified as having Marsh 0 had
in fact sub-microscopic changes (microscopic enteritis),
and we lack individual-based data on immunohistochem-
istry for our individuals [44,45]. Microscopic enteritis has
increasingly been recognized as an important cause of
CD-like symptoms including malabsorption [44]. These
individuals have a low count of intraepithelial lym-
phocytes but nevertheless show altered enterocytes and
affected microvilli [44]. Microscopic enteritis is also asso-
ciated with other autoimmune diseases.
Among individuals with normal mucosa but positive CD
serology and available data, we also characterized the use
of gluten-free diet. Approximately one individual in four
had received information about gluten-free diet from a
physician or from a dietician after having their biopsy.
However, some individuals with positive CD serology
may have had tried a gluten-free diet themselves, without
prior prescription. Among individuals on a gluten-free
diet, about half reported a clinical response. It has previ-
ously been shown that symptoms in individuals with
minor mucosal abnormalities may improve on a gluten-
free diet [46]. This supports our belief that at least some
individuals with normal mucosa but positive CD serology
have early stage CD or a phenotype of CD.
Conclusion
Individuals with positive CD serology but normal mucosa
often have CD-like symptoms and a family history of CD.
Such individuals may be identified through registry
matching.
A proportion of individuals with normal mucosa (Marsh
0) and positive CD serology may in fact have microscopic
enteritis[44]. Earlier research has shown that individuals
with macroscopically normal mucosa but positive CD
serology often progress to Marsh I-III with symptoms con-
sistent with CD[15,21].
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